
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Paris - Patch testing for possible contact allergy looks to be an effective tool in the investigation of inflammatory vulval diseases for patients with vulval dermatoses.